AN OPEN-LABEL, MULTI-CENTER, PHASE I/II STUDY TO ASSESS SAFETY, DISEASE PROGRESSION, AND CELLULAR KINETICS FOLLOWING YTB323 ADMINISTRATION IN PARTICIPANTS WITH NON-ACTIVE PROGRESSIVE MULTIPLE SCLEROSIS (PMS)
- Registry ID
- CYTB323R12101
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE1
- Study type
- INTERVENTIONAL
- Sponsor
- NOVARTIS PHARMACEUTICALS CANADA INC
- Start date
- 2026-02-04
- Last update
- 2024-09-20
Conditions
Related clinical trials
- A PHASE III, OPEN-LABEL, SINGLE-ARM, MULTI-CENTER STUDY TO EVALUATE THE SAFETY AND USE OF AN ON-BODY DELIVERY SYSTEM FOR THE SUBCUTANEOUS HOME ADMINISTRATION OF OCRELIZUMAB IN PATIENTS WITH MULTIPLE SCLEROSIS
- A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III STUDY TO EVALUATE THE
EFFICACY AND SAFETY OF REMIBRUTINIB IN PATIENTS WITH SECONDARY PROGRESSIVE
MULTIPLE SCLEROSIS
- A PHASE 2, RANDOMIZED, DOUBLE-BLIND, FOUR-ARM, PLACEBO-CONTROLLED, MULTICENTER STUDY ASSESSING THE EFFICACY, SAFETY AND TOLERABILITY OF THREE DOSES OF ORALLY ADMINISTERED BMS- 986368, A FAAH/MAGL INHIBITOR, FOR THE TREATMENT OF SPASTICITY IN PARTICIPANTS WITH MULTIPLE SCLEROSIS (BALANCE-MSS-1)
- THE DIFFERENTIAL EFFECTS OF THC VS. CBD ON COGNITION IN PERSONS WITH MS
- A RANDOMIZED, OPEN-LABEL, PARALLEL-GROUP, NON-INFERIORITY STUDY COMPARING
EFFICACY, SAFETY, AND TOLERABILITY OF REMIBRUTINIB AFTER SWITCHING FROM
OCRELIZUMAB IN PARTICIPANTS LIVING WITH RELAPSING MULTIPLE SCLEROSIS, FOLLOWED BY
OPEN-LABEL TREATMENT WITH REMIBRUTINIB
- A PHASE 2, RANDOMIZED, OBSERVER-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING
STUDY OF MRNA-1195 INTRAMUSCULAR INJECTION IN PARTICIPANTS 18 TO ¿55
YEARS OF AGE WITH EARLY MULTIPLE SCLEROSIS
View on source registry